FiercePharma1h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
pharmaphorum3d
Five lessons from GSK in social media
Does social media bring commercial benefits to GSK? That's not exactly the point, according to Quayle and Morgan. "Increasing sales is not one of our KPIs", says Morgan, "although building ...
The Pharma Letter5h
Dynamic pipeline powers GSK through vaccine worries
GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...
The Armenian Reporter3h
GSK (NYSE:GSK) Releases FY 2025 Earnings Guidance
GSK (NYSE:GSK – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.090-2.130 for the period, compared to the consensus earnings ...
FierceBiotech23d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.
The Business Journals23d
GSK shells out $1B upfront for Plymouth cancer biotech
chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...